Aurobindo Pharma USA New Jersey warehouse gets USFDA OAI status
Hyderabad: Aurobindo Pharma has announced that the United States Food and Drug Administration (US FDA) had conducted an inspection at one of the warehouses of Aurobindo Pharma USA Inc., (a 100% subsidiary of the Company), situated at East Windsor, New Jersey, from May 13, 2024 to May 15, 2024, with regards to compliance of the Drug Supply Chain Security Act (DSCSA).
The inspection had concluded with 5 observations.
Subsequently, the US FDA has determined the inspection classification status of this warehousing facility as ‘Official Action Indicated (OAI)’.
"At this point in time, the Company doesn’t foresee any impact on the business. The Company remains committed to work closely with the US FDA and continues to enhance its compliance on an ongoing basis," Aurobindo stated.
Read also: Aurobindo Pharma arm Eugia Steriles gets 5 UFSDA observations
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.